Member Info for elrico

You are right in what you say about customer sales will dictate if a product is a viable alternative to the competition. The review help and the vast majority ate 5 stars. The science also sets SlimBiome apart from the competition and don't forget, no other product has the cognitive effect of switch the brain off from sweet cravings.

Ref margins. The current £14.99 promo ends later this month, the 1@£18.99 and 2@£19.99 - I believe OPTI's cut is near £4.45 than £2 TW quotes. I am told I am closure to the figure than TW.

Remember, SlimBiome is heat resistant, so can go into a multitude of products, ranging from ice goods, dairy, baked goods, beverages, etc.

Having said all that, the products need promo, PR, etc. Agropur will also help build a very strong brand, as will H&B, especially if they replace boombod, whos sales a dropping. It is very early days of course and retail habits can change. So, this is our biggest risk. But, we have multiple shot at goal.

I guess some will be. H&B could be a significant soother - boxes of Slim Biome (as they call it) are flying resulting in the 2nd order from OPTI already.

https://www.agropuringredients.com/custom-solutions/blends/slimbiome-weight-loss-blend/

I'm not sure if it's just for SM, it's not TV campaign quality.

https://mobile.twitter.com/LEMMINGINVESTOR/status/1220071676706217986

Feb/March is my guess.

IMHO, a CEO should aim for conservative figures if put in the public domain (£4m FY 2020) because miss it by 20% it is essentially a profit warning - I doubt GB is so naive to be so clumsy. The flipside, PI can cause their own problem by getting giddy by predicting silly numbers. Let the company do the talking on this front.

The market is c6 month behind the company's development - Take advantage if you can, I have.

https://lemminginvestors.blogspot.com/

I am not saying you are wrong, but I strongly suspect you are. YSF usually declare sales and are usually placed. Has YSF suddenly become non-compliant? There is no evidence for this. I suspect the trust is closer to stale bulls and distressed sellers that have overstretched SB positions. The is just as much evidence of a short campaign, again, unlikely given there is no borrow.

There are a lot of myths around the requirement for NASDAQ listing, most notably out-of-date info on stocko site. Advisors have already informed OPTI they are good to go as-is for duel listing.

https://lemminginvestors.blogspot.com/2020/01/optibiotix-health-2019-trading-update.html

TW bought more OPTI. His comment after the pod on PS https://twitter.com/TomWinnifrith/status/1218201411726585856

Belgrano, nobody appears to note the Goetz report has £11m PLC costs up to 2026. The costs are sector standard. However, they do NOT apply to OPTI due to the business model. My point being, Goetz outperform which is heavily discounted and strip out c50% of the PLC costs, it should have a material difference to the SP, certainly well beyond the 97p.

There's no doubt there are potential investors with splinters in the seat waiting for the trading statement, no doubt concerned about the cash runway. This nonsense about poor cash position and placing ahoy will be quashed allowing us patient investors bask in the near certain recovery while the SP rises and the plastic bears head for the woods.

Nothing short of agreeing with what I have said via the lemming blog.

Believe me, I have tried to get SOH to elaborate on developments with SweetBiotix(s) - these are ongoing developments which take time, but when production/ingredients partners are confirmed these should have a positive boost to future confidence because the potential for SweetBiotix is huge.

These studies demonstrate something we investors have known for quite some time - in that the company what we could call a "magic bullet" enabling the treatment of both high cholesterol and high blood pressure in one tablet - as far as I am aware, this is not available by any other supplement and or medication through a health service. Of course, the company already has CholBiome x3 which also reduces hypertension. However, if I am correct, today's news allows for specific medical claims because both Nutrilinea's product which also contains OptiBiotix's LP-LDL will be common to both but other ingredients which work synergistically to help lower blood pressure and improve vascular health. Nutrilinea will have Europe (excluding UK) for 1 year from study data release, while OptiBiotix will have the ROW and then add Europe from next December.
https://lemminginvestors.blogspot.com/2020/01/optibiotix-health-successful-human.html

Dependant on retailer home brand or OPTI own.

And why I think some peoples perspective and understanding is misguided.

https://lemminginvestors.blogspot.com/2020/01/optibiotix-health-h-slimbiome-launch.html

The impact of functional foods on our microbiome, health and diet

https://www.youtube.com/watch?v=AqTI6Ri9k8g&feature=youtu.be

Yeah, sure. Care to tell us what happened in October?

A genuine question. Why would anyone with commonsense (Leaving aside intelligent thinking) take any notice of someone talking down OPTI without any serious analysis? Then he gets his cronies to post the same drivel. All said and done, your combines posts demonstrate you have done no research (if you have it does not show) or you simply have no vision, lack the skills to see what is developing in the food, beverage and health markets around the world, and no clue where OPTI is in this cycle of transition from R&D to commercial development where it is expected to be throwing off cash by H2 this year. Instead, you buy overhype companies like BIDS run by shady CEO's.

IQAI was 13.30p in October compared to 4.5p now. It's been around since 1995, so it's not a growth company is it!

Have a nice day.